Active Ingredient History

NOW
  • Now
Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the UK and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.   Wikipedia

  • SMILES: Clc1ccc(cc1)C(=O)NCCN2CCOCC2
  • InChIKey: YHXISWVBGDMDLQ-UHFFFAOYSA-N
  • Mol. Mass: 268.74
  • ALogP: 1.4
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

Australia

$0.1259 - $0.2490
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

4-chlor-n-(2-morpholinoethyl)benzamid | 4-chloro-n-(2-(4-morpholinyl)ethyl)benzamide | 4-chloro-n-(2-morpholin-4-yl-ethyl)-benzamide | auromid | aurorix | gnf-pf-695 | manerix | moclaime | moclamide | moclamine | moclobamide | moclobemid | moclobemida | moclobemide | moclobemidum | p-chloro-n-(2-morpholinoethyl)benzamide | ro-111163000

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue